Login | Register

Sector: Life Sciences

Enlarged Board of Appeal fails to offer clear guidance in highly-anticipated “plausibility” opinion
Enlarged Board of Appeal fails to offer clear guidance in highly-anticipated “plausibility” opinion

The EBA has not laid out clear rules about when post-filed evidence can be used to demonstrate technical effect

NuCana’s big-money damages hopes suffer blow as UK court backs Gilead in European dispute
NuCana’s big-money damages hopes suffer blow as UK court backs Gilead in European dispute

The High Court of England and Wales has shifted the momentum of the spat, with the EPO Technical Board of Appeal set to hear a related case tomorrow

Life Sciences correspondent

Thought leadership from industry experts
Latest content

New Delaware judge signs first multimillion dollar jury verdict

Judge Gregory Williams’ $42 million award to a patentee prompted a dive on Docket Navigator to examine his track record to date

27 February 2023

Vidal reveals perspective on UPC, SEPs and competition with China

In the second part of IAM’s exclusive interview with USPTO Director Kathi Vidal, she shares her thoughts on international patent issues

23 February 2023

What Big Tech can learn from pharma on innovator diversity

Featured in Special Report 2023 Q1: Advancing IP Diversity

23 February 2023

Unitary SPCs necessary to attract pharma to UPC/UP system, says Bayer IP chief

Joerg Thomaier also shares his thoughts on the UPC and EPO patent quality in an exclusive IAM interview

22 February 2023

Amgen v Sanofi highlights growing ambiguity of pharma IP strategies

Saturday Opinion: SCOTUS enablement review has exposed divisions among innovative life sciences companies

18 February 2023

Indian court hands hefty fine to generic drug boss who ignored Pfizer patent injunction

Triveni Interchem and its director deliberately flouted sales ban, rules Delhi judge

14 February 2023

US legislators and government agencies take aim at pharma patent strategies

The Senate Judicial Committee has advanced several IP bills targeting life sciences rights owners

13 February 2023

Patent strategies for protecting bioinformatics inventions

As bioinformatics and computational genomics companies push the boundaries of technology, it is important they overcome subject matter eligibility challenges to protect their innovations

08 February 2023

Boston Scientific ordered to hand University of Texas $42 million in David-versus-Goliath dispute

But patentee worried further action could ‘exhaust’ it as MedTech company moves to appeal

07 February 2023

The fast-evolving cannabis patent dispute landscape

GW’s recent ANDA lawsuit is a landmark moment, but will remain untypical of cannabis IP litigation

06 February 2023

Unlock unlimited access to all IAM content

Subscribe Now